The recognition of VEGF’s involvement in tumor angiogenesis has led to the development of anti-angiogenic therapies aimed at inhibiting the VEGF pathway to deprive tumors of blood supply, thus inhibiting their growth and metastatic potential [12]. This evidence concerns the gene VEGFA and neoplasm.